Supplementary Table 1 Relation between baseline cardiometabolic risk factors and albumin-bilirubin on 8-year liver-related complications

Indicators	Univariable odds ratio	Multivariable prognostic odds ratio (95%CI)		
	(95%CI)	Based-prognostic score	Based-prognostic score	
			plus ALBI	
Age (year)	1.04 (1.02 – 1.05)	1.02 (1.00 – 1.04)	1.02 (1.00 - 1.04)	
Male	0.98 (0.65 – 1.48)	Not included	Not included	
CAP (dB/m)	1.00 (0.99 – 1.01)	Not included	Not included	
Overweight / Obesity	1.06 (0.61 – 1.82)	Not included	Not included	
Hypertension	1.61 (1.04 – 2.52)	1.44 (0.91 – 2.82)	1.61 (1.00 – 2.59)	
Prediabetes/Diabetes	1.73 (0.90 – 3.32)	Not included	Not included	
Hypertriglyceridemia	1.37 (0.88 – 2.15)	Not included	Not included	
Low HDL	1.47 (0.94 – 2.28)	Not included	Not included	
LSM (kPa)	1.02 (1.01 – 1.04)	1.00 (0.98 – 1.02)	0.99 (0.96 - 1.01)	
FIB-4	1.19 (1.11 – 1.27)	1.16 (1.07 – 1.26)	1.08 (0.99 - 1.17)	
ALBI	4.17 (2.90 – 5.97)	Not included	3.79 (2.37 – 6.05)	
constant		0.0140532	1.003886	

Abbreviation: ALBI, albumin-globulin; CAP, controlled attenuation parameter; FIB-4, fibrosis-4; HDL, high density lipoprotein; LSM, liver stiffness measurement

Supplementary Table 2 Relation between baseline cardiometabolic risk factors and albumin-bilirubin on 8-year all-cause mortality

Indicators	Univariable odds ratio	Multivariable prognostic odds ratio (95%CI)		
	(95%CI)	Based-prognostic score	Based-prognostic score	
			plus ALBI	
Age (year)	1.05 (1.03 – 1.07)	1.05 (1.02 – 1.07)	1.04 (1.02 - 1.06)	
Male	1.55 (0.99 – 2.43)	Not included	Not included	
CAP (dB/m)	0.99 (0.99 - 1.00)	0.99 (0.99 – 1.00)	1.00 (0.99 - 1.00)	
Overweight / Obesity	0.49 (0.30 - 0.81)	Not included	Not included	
Hypertension	1.23 (0.77 – 1.97)	Not included	Not included	
Prediabetes/Diabetes	1.50 (0.76 – 2.98)	Not included	Not included	
Hypertriglyceridemia	0.91 (0.54 - 1.53)	Not included	Not included	
Low HDL	1.22 (0.74 – 2.01)	Not included	Not included	
LSM (kPa)	1.05 (1.04 – 1.07)	1.05 (1.03 – 1.06)	1.03 (1.01 - 1.05)	
FIB-4	1.28 (1.18 - 1.39)	1.11 (1.03 – 1.20)	0.98 (0.89 - 1.08)	
ALBI	13.11 (7.98 – 21.53)	Not included	8.69 (5.00 - 15.10)	
constant		0.0204463	6.815334	

Abbreviation: ALBI, albumin-globulin; CAP, controlled attenuation parameter; FIB-4, fibrosis-4; HDL, high density lipoprotein; LSM, liver stiffness measurement

Supplementary Table 3 Prognostic performance of albumin-bilirubin and other non-invasive scores on 8-year liver-related complications and all-cause mortality

Scores	Advance fibrosis (n=	Advance fibrosis (n=261)		Non-advance fibrosis (n=902)		
	8-year liver-related	8-year all-cause	8-year liver-related	8-year all-cause		
	complications		complications	mortality		
ALBI				_		
AuROC (95%CI)	0.76 (0.67 – 0.85)	0.86 (0.79 – 0.93)	0.68 (0.62 – 0.75)	0.74 (0.67 - 0.81)		
Euclidian cutoff values	≥-2.61	≥-2.54	≥-2.89	≥-2.89		
Sensitivity/Specificity (%)	68.57 / 69.91	81.40 / 79.82	64.62 / 64.87	67.44 / 64.26		
PPV/NPV (%)	26.09 / 93.49	44.30 / 95.60	12.50 / 95.94	8.63 / 97.53		
Positive/Negative LR	2.28 / 0.45	4.03 / 0.23	1.84 / 0.55	1.89 / 0.51		
Correctly classified (%)	69.73	80.08	64.86	64.41		
FIB-4						
AuROC (95%CI)	0.67 (0.56 – 0.79)	0.72 (0.63 – 0.80)	0.60 (0.52 - 0.68)	0.61 (0.51 – 0.71)		
Euclidian cutoff values	≥2.99	≥3.05	≥1.16	≥1.16		
Sensitivity/Specificity (%)	65.71 / 64.16	62.79 / 65.14	56.92 / 58.42	58.14 / 58.09		
PPV/NPV (%)	22.12 / 92.36	26.21 / 89.87	9.61 / 94.58	6.49 / 96.52		
Positive/Negative LR	1.83 / 0.53	1.80 / 0.57	1.37 / 0.74	1.39 / 0.72		
Correctly classified (%)	64.37	64.75	58.31	58.09		
Comparison of AuROC*						

ALBI vs FIB-4	0.087	<0.001	0.126	0.011	

<sup>\*</sup> p-value by DeLong test, significant level at p<0.05